Form 4: Director James Intrater Acquires CDIO Stock Options

Cardio Diagnostics Holdings, Inc. director James Intrater was granted 3,205 stock options as part of a compensation event.

Summary

• Director James Intrater acquired 3,205 stock options in Cardio Diagnostics Holdings, Inc. (CDIO).
• The options have an exercise price of $1.95 per share.
• The grant date and initial exercisability date is March 31, 2026.
• The options expire on March 31, 2036.
• Following this transaction, the reporting person holds a total of 10,464 derivative securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Dilutive impact of new option grants on existing shareholders.

Risks

• Market price volatility affecting the value of the granted options.
• Potential for future dilution if options are exercised.

Future Outlook

The filing does not provide forward-looking guidance regarding company performance, only the terms of the equity grant.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term performance and align leadership with shareholder outcomes in the biotechnology and diagnostics sector.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is consistent with standard practices for small-cap growth companies.
• The 10-year expiration term is standard for executive and director equity incentive plans.

Stakeholder Impact

• Minor dilution for existing shareholders upon potential future exercise of options.

Next Steps

• The reporting person may exercise these options starting March 31, 2026, until their expiration in 2036.

Key Dates

Keywords

CDIO, Cardio Diagnostics, Insider Trading, Form 4, Stock Options, Director Compensation